Ludmilla Pinto Guiotti Cintra Abreu

Ludmilla Pinto Guiotti Cintra Abreu

Auto-generated profile, based on publicly available information

Ludmilla Pinto Guiotti Cintra Abreu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2026 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Open access
BMBrenda de S. Moreno
Brenda de S. Moreno
LALudmilla P. G. C. Abreu
Ludmilla P. G. C. Abreu
GSGabriella de Oliveira Silva
Gabriella de Oliveira Silva
LSLucas M Syllos
Lucas M Syllos
JSJhenyfer Benício Santos
Jhenyfer Benício Santos
MCMARCELLA CARNEIRO
MARCELLA CARNEIRO

5 May 2026 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Verified
Journal Article
Open access
GLGlécia Virgolino da Silva Luz
Glécia Virgolino da Silva Luz
LALudmilla Pinto Guiotti Cintra Abreu
Ludmilla Pinto Guiotti Cintra Abreu
NPNashira Vieira O’REilly Cabral Posada
Nashira Vieira O’REilly Cabral Posada
RARonaldo Gonçalves Abreu
Ronaldo Gonçalves Abreu
GSGleide Célia Virgolino da Silva
Gleide Célia Virgolino da Silva
MCMARCELLA CARNEIRO
MARCELLA CARNEIRO
Introduction: Cosmetics formulated with nanotechnology (1.0 x 10–⁹ m) have great market potential due to their effectiveness and consumer satisfaction. Objective: To conduct a documentary review of international regulatory requirements related to the safety of cosmetics containing nanomaterials. Method: A systematic documentary analysis was performed using official websites of eight regulatory agencies: the United States, European Union, Canada, Japan, Australia, China, India, and South Korea. The research was structured using the PICOT acronym. Documents were screened based on inclusion and exclusion criteria and evaluated by peer reviewers. Data extraction was conducted using REDCap® software and organized into thematic frameworks. Results: Nine documents were included, with emphasis on those issued by the SCCS (EU), FDA (USA), ICCR, and MHLW (Japan). Regulatory convergence was observed in aspects such as the physicochemical characterization of nanomaterials (including size, morphology, purity, and stability) and the requirement for specific testing related to dermal irritation, inhalation toxicity, genotoxicity, and skin absorption. The analyzed documents highlight that nanomaterials may exhibit physicochemical properties, biological interactions, and toxicological effects distinct from the same ingredients on a conventional scale — with magnetic, optical, structural, electrical, and chemical differences that may impact product performance, safety, and efficacy. Conclusions: There is no international regulatory consensus on mandatory criteria for the useof nanomaterials in cosmetics. Agencies recommend multiple validated tests, applied to different product batches, and emphasize the importance of detailed physicochemical characterization as well as dose–response assessment as essential requirements. The experience of more established jurisdictions can support the advancement of the Brazilian regulatory framework in this emerging field.